Pomerantz Law Firm Investigates Potential Securities Fraud at ClearPoint Neuro, Inc.
Pomerantz LLP has launched an investigation into ClearPoint Neuro, Inc. (NASDAQ: CLPT) following a significant drop in its stock price. The inquiry seeks to determine if the company or its executives engaged in securities fraud or unlawful business practices related to recent clinical developments. The scrutiny follows a September 29, 2026, announcement from development partner uniQure N.V. regarding Phase I/II studies for ifezuntirgene inilparvovec, a treatment for Huntington's disease. The data revealed that the treatment failed to achieve statistical significance on a primary clinical measure at the 48-month mark. In response to this news, ClearPoint Neuro's stock price plummeted by $3.54 per share, representing a 23.12% decline to close at $11.77.
Topics: class action lawsuit clinical trial failure securities fraud investigation stock price drop
Read the full article at PR Newswire
Part of the story Pomerantz Law Firm Investigates Potential Securities Fraud at ClearPoint Neuro, Inc. (3 articles)